Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
In the latest trading activity, Cathie Wood’s ARK ETFs have made significant moves in the stock market on Wednesday, August 13, 2025. The renowned investment management firm has continued to adjust its portfolio, with a notable emphasis on Bullish (BLSH), Shopify Inc (NYSE:SHOP), and Guardant Health Inc (NASDAQ:GH).
Topping the list of ARK’s transactions was the purchase of a staggering 2,532,693 shares of Bullish, distributed among ARKK, ARKW, and ARKF ETFs, with a total dollar value of approximately $93.7 million. This move indicates a strong bullish stance on the cryptocurrency exchange platform, as ARK invests heavily in what it believes could be a future leader in the digital assets space.
On the healthcare front, ARK has shown a continued interest in CareDx Inc (NASDAQ:CDNA) and GeneDx Holdings Corp (NASDAQ:WGS), buying 56,939 and 17,723 shares respectively. The investments, valued at approximately $709,459 for CareDx and $2,063,134 for GeneDx, reflect ARK’s confidence in the genetic diagnostics and personalized medicine sectors.
Conversely, ARK has decided to offload some of its holdings in the precision oncology company Guardant Health, selling 25,752 shares through its ARKG ETF, amounting to about $1.4 million. This sale, along with a divestment of 93,988 shares of 908 Devices Inc (NASDAQ:MASS) valued at $608,102, suggests a strategic retreat from certain positions within the healthcare technology industry.
Additionally, ARK has reduced its exposure to e-commerce giant Shopify, selling 21,240 shares through the ARKF ETF with a total value of over $3.1 million. This move comes amidst a broader sell-off trend observed in Shopify’s stock by ARK over the past week, indicating a potential shift in the firm’s assessment of the online retail sector’s prospects.
Investors also witnessed ARK’s continued accumulation of Personalis Inc (NASDAQ:PSNL) shares, with the latest purchase of 15,263 shares valued at $69,751. This follows a series of buys in the genomic sequencing company over the past week, highlighting ARK’s growing interest in the genomics industry.
As market participants analyze these trades, it’s clear that Cathie Wood’s ARK ETFs are actively managing their portfolio, capitalizing on perceived growth opportunities while also making strategic exits. Investors will undoubtedly keep a close eye on these developments to gauge the direction of ARK’s innovative investment strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.